To evaluate if an integrin-retargeted adenoviral vector could establish a more efficient and tumor-specific gene transfer in esophageal carcinoma cells. Summary Background Data: Although preclinical data indicated that adenoviral gene therapy could be a promising novel treatment modality for various malignancies, clinical results are often disappointing. An important problem is the decreased tumoral expression of the Coxsackie and adenovirus receptor (CAR), which mediates adenoviral entry. Retargeting the adenoviral vector to other cellular receptors, by inserting an arginine-glycine-aspartate (RGD) tripeptide in the fiber knob, might overcome this problem. Methods: Four esophageal carcinoma cell lines and 10 fresh surgical resection specimens were cultured. All were infected with the native adenovirus (Ad) and the retargeted adenovirus (AdRGD), encoding for the reporter genes luciferase or Green Fluorescent Protein to analyze gene transfer efficiency. Results: In all cell lines, an increase in viral expression per cell and an increase in the percentage of transduced cells were seen with the retargeted adenovirus. Also, in the primary cultures of carcinoma cells, a more efficient gene transfer was seen when the retargeted vector was used. This phenomenon was less pronounced in normal cells, indicating that the RGD virus transduces tumor cells more efficiently than normal cells. Conclusions: This study demonstrates that an RGD retargeted adenovirus infects human esophageal carcinoma cells with enhanced efficiency, while in normal esophageal cells this effect is less pronounced. Therefore, this retargeted vector is expected to have a From the
E sophageal cancer is a highly aggressive disease with poor long-term outcome. So far, surgical resection is still the treatment of choice when curation is sought. However, this treatment is associated with high morbidity and mortality, and even after potentially curative surgery, 5-year survival rates rarely exceed 25%. 1 Therefore, new approaches in the treatment of this malignancy are considered. Gene therapy with adenoviral vectors seems a promising novel treatment modality for various malignancies in preclinical studies, 2, 3 but so far clinical results are often disappointing. This is at least partly due to the following two important problems.
First, there is a significant discrepancy between the adenoviral vector efficacies observed in vitro using established cell lines and the tumor transduction rates achievable in in vivo delivery. 4 Although carcinoma cell lines are valuable tools for investigating various aspects of transduction efficiencies, only specific cell types can be studied. In addition, these cells consist of a monolayer of monoclonal tumor cells, which are transformed due to multiple passages with limited similarity to the heterogeneous carcinoma cell population in vivo. Therefore, it would be desirable to have a culture system of primary cells to study adenoviral transduction in cells more comparable with the in vivo situation.
A second important limitation of the in vivo application of the current adenoviral cancer gene therapy is the resistance of carcinoma cells to adenoviral infection. Adenoviral entry into target cells is the rate-limiting step of gene delivery. The initial binding of an adenovirus to the cell surface is a receptor-mediated process; therefore, efforts have been made to characterize the cellular receptors of the adenovirus. Recently, one of the adenoviral receptors on the surface of a host cell was identified as the Coxsackie and adenoviral receptor (CAR), which is a protein that is also involved in maintaining tight junction integrity. 5, 6 Upon binding of the knob domain of the viral fiber protein to CAR, the virion enters the cell through the interaction of its penton base with the ␣ v ␤ 3 and the ␣ v ␤ 5 integrins on the host cell surface. 7 This is followed by the internalization of the virus within a clathrin-coated endosome. Finally, the virus escapes the endosome, translocates to the nuclear pore complex, and releases its genome into the nucleoplasm where subsequent steps of viral replication take place ( Fig. 1) .
Several investigations have revealed a decrease in expression of the CAR protein in neoplastic cells, which may explain the low transduction efficiency of carcinoma cells seen in vivo. 7, 8 To overcome the limitations imposed by the CAR dependence of adenoviral infection, targeting can be used by genetically modifying the fiber knob, enabling the virus to attach and infect via another cell surface receptor. Since tumor cells express integrins abundantly, a retargeted adenoviral vector with an arginine-glycine-aspartate (RGD) peptide inserted into the HI-loop of the fiber knob might solve the problem of poor transduction of tumor cells by allowing a CAR-independent gene transfer directly through integrins. 9 The first aim of this study was to establish a culture system from fresh surgical resection specimens to study adenoviral transduction in cells more comparable with the in vivo situation. An additional advantage of such a system is that apart from analyzing infection percentages in (heterogeneous) carcinoma cells of various patients, the transduction efficiencies of adenoviral vectors in carcinoma cells can directly be compared with normal squamous mucosal cells of the same patient.
The secondary aim of this study was to analyze the efficiency of the genetically retargeted vector for esophageal carcinoma in comparison with the native adenovirus. The RGD-retargeted adenovirus was tested on four established human esophageal carcinoma cell lines and on 10 primary cell cultures from fresh surgical esophageal resection material. Because primary cultures of human material will contain various cell types (especially fibroblasts, lymphocytes, and hematopoietic cells) in addition to cancer cells, 10 -12 we subsequently characterized the origin of the cells that were infected by both vectors.
MATERIALS AND METHODS

Established Esophageal Carcinoma Cell Lines
The human esophageal adenocarcinoma cell lines OE19 and OE33 were purchased from the European Collection of Cell Cultures (Salisbury, UK). The squamous cell carcinoma cell lines TE1 and TE2 have been isolated and characterized at Tohoku University (Sendai, Japan). 13 These cell lines were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 300 g/mL L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (DMEM/ 10% FCS/ L-glu/ Pen/ Strep), at 37°C in a humidified, 10% CO 2 atm.
Primary Cell Cultures of Esophageal Resection Specimens
This study was performed in accordance with the guidelines of the local ethics committee. In The Netherlands, a written informed consent is not required to perform additional experiments on primary resected material.
In patients who underwent subtotal esophageal resection and proximal gastrectomy with curative intent for adenocarcinoma of the esophagus or gastroesophageal junction or squamous cell carcinoma of the esophagus, the left gastric artery was preserved until the end of the resectional phase of 
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Annals of Surgery • Volume 238, Number 6, December 2003 the operation to maintain maximal viability of the removed specimen. Samples of normal squamous esophageal mucosa without the underlying submucosal connective tissue and proper muscle, and vital tumor (assigned by experienced GI pathologists G.J.A.O. or F.T.K.) were collected, washed in phosphate-buffered saline (PBS), and minced into small pieces. The fragments of mucosa or tumor were resuspended in 10 mL Liver Digest Medium (Life Technologies, Breda, The Netherlands) and floated in a shaking waterbath at 37°C. After 2 hours, the supernatant containing dissociated cells was decanted, supplemented with 50% fetal calf serum, and centrifuged (1500 rpm/min for 5 minutes at 4°C). The single cells were resuspended in cold culture medium (DMEM/ 10% FCS/ L-glu/ Pen/ Strep) and stored on ice until use. The dissociation step was repeated with fresh Liver Digest Medium three times. All dissociated cells obtained per tissue sample were pooled and applied to tissue culture plates coated with collagen type IV. Two X 10 5 cells in a well of a 24-well plate or in iso-concentration in 6-well plates were cultured for 24 hours in 0.5 mL DMEM/ 10% FCS/ L-glu/ Pen/ Strep supplemented with 0.1 mg/mL Fungizone, in a humidified atmosphere containing 10% CO 2 at 37°C.
Adenoviral Constructs
The native adenoviral vectors (Ad), derived from human adenovirus type 5, were obtained from R.D. Gerard (University of Leuven, Leuven, Belgium). For adenoviral transduction analysis, the adenovirus was made replication deficient by deleting the E1 region. Into this deleted E1 region, the reporter genes luciferase (Adluc) and Green Fluorescent Protein (AdGFP) were cloned and constructed to be driven by the human cytomegalovirus promoter. These reporter genes were used to analyze viral transduction levels by measuring the amount of luciferase and GFP transcription.
The genetically retargeted adenoviral vectors containing the recombinant RGD (Arg-Gly-Asp) peptide in the HI-loop of the fiber knob were generated by transfection of 293 cells with PacI-digested pVK703, 14 and constructed to encode for either the luciferase or GFP reporter gene (AdlucRGD and AdGFPRGD, respectively). 9 The viral vectors were propagated on the permissive cell line 293 and purified by double cesium chloride gradient centrifugation. 15 All virus preparations were dialyzed against PBS, aliquoted, and stored at -80°C until use. Adenovirus titers in plaque forming units (pfu) were determined in parallel by a plaque forming assay using 293 cells, and the number of viral particles (vp) was measured by optical density-based physical titration. The vp/pfu ratios of the native vectors were 10 to 20 and those of the RGD-modified vectors were 40 to 50.
Adenoviral Gene Transfer
The adenoviral transduction experiments on the four cell lines were performed in triplicate. Cell lines were grown overnight at a count of 1 X 10 6 cells/well in 6-well plates to allow adherence. The monolayers of cells were then washed with PBS, and incubated for 1 hour with the different adenoviral constructs at various multiplicity of infection of 1, 10, and 100 pfu/cell. Then, complete fresh medium was added, and after 24 hours of incubation, the luciferase and GFP expression was analyzed for the different viral constructs. For all experiments, a sample of cells in which no virus was added was used as a negative control.
After cell lysis, quantitative levels of viral luciferase production in the cells were measured in a luminometer (Berthold Detection System, Pforzheim, Germany) using a luciferase assay system (Promega, Madison, WI). The protein concentration of the lysates was determined with a protein assay (Pierce Biotechnology, Rockford, IL).
Infection percentages were analyzed by determining the percentage of GFP expressing cells by fluorescence activated cell scanning (FACS; BD Biosciences, San Jose, CA). Cultured cells were trypsinized, washed in PBS, and fixated in 1 mL 2% paraformaldehyde. After centrifuging the cells at 1000 rpm for 5 minutes, the cells were resuspended in PBS with 1% bovine serum albumin. The percentage of transduced cells was determined by gating the right-hand tail of the distribution of the negative control sample for each individual cell line at a 1% positivity (based on the negative control results), which was considered as autofluorescence of the cell line.
To analyze adenoviral transduction levels in primary cells, the single cells were cultured for 24 hours after isolation. Then, cultures were rinsed with PBS and vital cells (ie, cells attached to the collagen coating) were exposed to the different adenoviral vectors as described above. Dependent on the amount of primary cells available, the experiments were performed at least in duplicate at various multiplicities of infection. For quantitative viral expression levels, cells were infected with Adluc or AdlucRGD and lysed after 24 hours for luciferase measurement. The transduction ratio (ie, luciferase activity per sample infected with AdlucRGD divided by the luciferase activity per sample infected with Adluc) was used to analyze the differences between gene transfer increase in carcinoma cells and normal epithelial cells from the same patient.
To analyze if the quantitative increase in viral expression levels was due to an increase in the number of transduced cells or an increase in the viral expression per cell, the primary cultures were also infected with AdGFP and AdGFPRGD and analyzed by fluorescence microscopy.
Characterization of Primary Cultures
Three of the 10 primary cultures infected with AdGFP and AdGFPRGD were used to characterize the origin of the different primary cells and to determine the infection percentages of the various cell types by two-color flow-cytometric analysis. Cells were trypsinized, washed, and resuspended in PBS-Tween (0.2%) to make the cells permeable for the detection of intracellular cytokeratin proteins by FACS analysis. Cytokeratins are part of the cytoskeleton of epithelial cells and are not present in fibroblasts and other stromal cells. All cells were incubated for 60 minutes with saturating concentration of the MNF116 mouse-antihuman cytokeratin monoclonal antibody (DAKO, Glostrup, Denmark), 16 which reacts with human epithelial tissue and malignant epithelial lesions. Cells were then washed 3 times in PBS and incubated for another 60 minutes with the secondary fluorescein-isothiocyanate-labeled goat antimouse immunoglobulin G antibody (Jackson, Westgrove, PA). After 3 more washing steps, the cells were resuspended in 1 mL 2% paraformaldehyde. As a negative control, an aliquot of cells from each patient was used in which control IgG was added to the cells without previous labeling with MNF116. The percentage of transduced epithelial cells was analyzed by determining the percentage GFP positivity and cytokeratin positivity per primary cultured tissue by quadrant statistics after two-color flow cytometry.
Statistical Analysis
To analyze if the increase in luciferase activity with the retargeted adenoviral vector was significantly higher in carcinoma cells than in normal squamous epithelial cells, a parametric Student t test was used to compare the transduction ratios of the primary cells. A P value of Յ0.05 was considered statistically significant. The statistical analysis was performed using the Statistical Software Package version 11.5 (SPSS Inc., Chicago, IL).
RESULTS
Adenoviral Gene Transfer in Established Esophageal Carcinoma Cell Lines
To compare the efficiency in gene transfer of the parental virus to the genetically modified virus, the four esophageal carcinoma cell lines were infected with Adluc and its retargeted variant AdlucRGD as described in "Materials and Methods." A dramatic augmentation of luciferase activity was seen with the vector containing the Arg-Gly-Asp (RGD) peptide inserted into the HI-loop of the fiber knob ( Fig. 2) . With a multiplicity of infection of 1 and 10 pfu/cell, AdlucRGD demonstrated in the esophageal carcinoma cell lines OE19, OE33, TE1, and TE2 an approximately 250-, 30-, 300-, and 700-fold increase, respectively, in luciferase activity, compared with the cells infected with the parental virus. With a multiplicity of infection of 100, this increase was less pronounced, but there was still an 80-, 10-, 150-, and 400-fold enhancement in viral expression for the carcinoma cell lines with AdlucRGD.
To analyze whether this enhancement was due to an increase in luciferase expression per cell or an increase in number of cells infected, the experiments were repeated with the viruses encoding GFP. With all experiments, an increase in the percentage of infected cells with the AdGFPRGD vector was seen for all four cell lines (Fig. 3 ). In addition, there was also an increase in the intensity of fluorescence per cell, as was seen by the shifting of the bulk of the cells to the right. This indicates that the increase in luciferase expression seen with AdlucRGD is caused by both an increased expression per cell as well as a higher percentage of infected cells.
Adenoviral Gene Transfer in Primary Cell Cultures of Esophageal Resection Specimens
Promising results in established cell lines do not always reliably predict efficient adenoviral transduction of carcinoma cells in vivo. Therefore, 10 cultures of both normal esophageal epithelium and carcinoma cells were established as described in "Materials and Methods." This primary material was derived from 6 men and 4 women with a median age of 62 years (range 46 -82 years). Three patients had a distal esophageal adenocarcinoma developed in a Barrett segment, 4 patients had an adenocarcinoma of the cardia, and 3 patients had a squamous cell carcinoma. The tumor characteristics are described in Table 1 .
All 10 primary cultures were infected with the four viral constructs expressing either luciferase (Adluc and AdlucRGD) or GFP (AdGFP and AdGFPRGD). The increase in viral luciferase expression of the retargeted viral vector versus the parental vector is shown for both the carcinoma cells and the normal squamous epithelial cells in Figure 4A and B. In all patients, an increase in viral expression was seen with AdlucRGD versus the native adenoviral vector, varying from a 5-to almost a 100-fold increase. This transduction ratio for both normal squamous epithelial cells and carcinoma cells is shown in Figure 4C . The increase in gene transfer was significantly less pronounced in normal cells (P ϭ 0.03). In combination with the fact that the absolute luciferase expression of AdRGD was higher in carcinoma cells than in normal cells, this suggests a more specific transduction of esophageal carcinoma cells by the RGD retargeted adenoviral vector.
To analyze whether this increase in viral expression represented more transduced cells or an increase in viral expression per cell, all primary cultures were also infected with both the parental AdGFP and the genetically retargeted variant AdGFPRGD, and subsequently analyzed by fluorescence microscopy. It was demonstrated that with the retargeted virus both the number of infected cells, and the fluorescence intensity per cell increased in all cultures (Fig. 5 , upper panels). However, the cultures of primary tumor material seemed to contain two cell populations with different morphology. About 50% of the cells revealed a fibroblast-like morphology, and most likely are stromal cells. The remaining cells showed a more epithelial cell-like shape and probably are cancer cells (Fig. 5, lower panels) . These data therefore suggest that the increased transduction of the primary cultures might result from a better transduction of stromal cells, cancer cells, or both.
Characterization of Infected Cell Types
To discriminate between tumor cells and stromal cells, the primary cultures of patients 1, 3, and 6, were analyzed by flow cytometry for the epithelial cytokeratin marker MNF116. As expected, the primary cultures were indeed a mixture of cells from different origin. To analyze differences in the transduction efficiency of AdGFP and AdGFPRGD in both tumor cells and stromal cells, a two-color FACS analysis for GFP positivity and cytokeratin positivity was performed for the three primary cultures (Fig. 6 ). The percentages of uninfected epithelial cells (GFP-negative and MNF116-positive), infected epithelial cells (GFP-positive and MNF116-positive), uninfected stromal cells (GFP-negative and MNF116negative), and infected stromal cells (GFP-positive and MNF116-negative) per culture were analyzed by quadrant statistics. The increase in percentage of transduction with AdGFPRGD was determined for the different cell populations. In these three cultures, an increase was seen of 13.8%, 28.7%, and 4.5%, respectively, in the percentage of transduced epithelial cells, and an increase of 30.0%, 23.3%, and 8.1%, respectively, in the percentage of transduced stromal cells when compared with infection with AdGFP. These results indicate that the RGD retargeted adenovirus infected FIGURE 2. Adenovirus-mediated gene transfer of the parental adenoviral vector and the integrin retargeted adenoviral vector, both encoding luciferase (Adluc and AdlucRGD, respectively) to human esophageal carcinoma cell lines (OE19, OE33, TE1, and TE2). Cells were infected with either virus at a multiplicity of infection of 1, 10, or 100. Luciferase levels were corrected for the protein concentration and are shown in light units (LU)/mg protein. Background luciferase activity in the samples in which no virus was added (negative control) is also shown.
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Gene Therapy for Esophageal Carcinoma both primary epithelial cells and stromal cells more efficiently.
DISCUSSION
In this study, the utility of a retargeted adenoviral vector containing an RGD peptide in the HI-loop of the fiber knob was examined for gene therapy for esophageal carcinoma. It was shown that the retargeted virus had a 5 to 800 times more efficient gene transfer than the native virus in established esophageal cancer cell lines and in primary cul-tured esophageal carcinoma cells. Since the transduction increase was significantly less pronounced in normal cells with AdRGD and the adenoviral transgene levels were higher in carcinoma cells, the retargeted adenoviral vector was also demonstrated to be more efficient for carcinoma cells than the parental virus. The observation that a higher percentage of carcinoma cells is transduced with a more specific gene transfer is of clinical importance because the therapeutic effect of gene therapy will depend on efficient gene transfer to carcinoma cells and with fewer viral particles needed for the same therapeutic effect, the vector-related toxicity is likely to be decreased. Gene therapy, although originally developed for correction of genetic deficiencies of inherited disorders, has become a promising therapeutic entity for various carcinomas. 3 In cancer gene therapy, therapeutic genes are introduced into tumor cells aiming at arrest of tumor growth. To compete with conventional therapeutic modalities, cancer gene therapy should be both safe and effective. Targeting of vectors can be used to increase both the selective transduction and the transduction efficiency. Genetic targeting by inserting the tripeptide RGD into the HI-loop of an adenoviral vector was previously demonstrated to enhance infection of ovarian, pancreatic, and head-and-neck carcinomas with promising in vitro results. [17] [18] [19] [20] Despite promising adenoviral cancer gene therapy results in preexisting cell lines, so far only 2 of the more than 500 approved clinical trials are being evaluated in a phase III clinical trial due to disappointing results in vivo. 21, 22 To be able to analyze gene therapy vectors in cells more resembling the in vivo situation, a culture system was successfully established from fresh surgical resection specimens. Culturing gastrointestinal mucosa has been proven to be extremely difficult. 23 We also encountered several difficulties of this primary culture system. It was noted that preserving the left gastric artery intact until the end of the resectional phase of the operation was important to maintain maximal viability of the esophageal cells. Sometimes a fungal overgrowth developed (especially in specimens from patients with an obstructing tumor or candida esophagitis), or the viability of the cultures was limited (especially in specimens from patients with an ulcerating tumor). However, ultimately our established culture system was reproducible and unique in allowing a comparison of gene transfer in primary carcinoma cells and normal squamous epithelial cells.
Apart from epithelial cells, primary cultures established from fresh surgical resection specimens were demonstrated to contain stromal cells that are also more efficiently transduced with the retargeted virus. Due to the artificial culturing conditions, these primary cultures will probably contain a relatively high percentage of fibroblasts, which are susceptible for viral infection. 12 However, fibroblasts will also be present in the stroma of a primary tumor. Thus, transduction of stromal cells may also play a role in vivo. On the one hand, transduction of stromal cells might have a positive therapeutic effect because the vitality of a tumor is at least partly dependent on its stroma, and attacking these stromal cells may result in a more efficient gene therapy, but on the other hand, tumoral stroma is considered a barrier limiting tumor expansion, 24 and tumors lacking stromal cells have been reported to be more aggressive and to induce more metastases. 25 This phenomenon therefore implies that transduction of stromal cells may counteract the therapeutic possibilities of nonreplicating cytotoxic adenoviral vectors in cancer gene therapy.
For treating neoplastic diseases, carcinoma cells should be efficiently transduced and killed. In previous studies of our group, it was demonstrated that the absolute luciferase expression after viral transduction is representative for the amount of cell kill with a suicide gene. 17 However, nonreplicating adenoviral vectors encoding suicide genes were demonstrated to be not the most efficient vectors to be used in a clinical setting. Nowadays, conditionally replicating adeno- viruses (CRAds) represent a promising and novel way for cancer gene therapy. 26 These agents are designed to replicate specifically in tumor cells, followed by the spread of the viral progeny to neighboring cancer cells. This specific replication will at the same time prevent the adverse effects that could be caused by infection of stromal cells. An example is the ONYX-015 virus, which has been modified in the early regulatory protein E1b that normally allows the virus to bind and inactivate the host p53 gene to promote its own replication. The mutated adenovirus, however, only replicates in and lysis human cells with a defective p53 pathway. 27, 28 This virus is expected to be especially useful in esophageal carcinomas since for this malignancy a p53 mutation is the most frequent alteration identified (75-100%). 29 It has also been demonstrated that p53 mutations are an early event during the malignant degeneration of esophageal cells. 29 Therefore, this virus could even be used for the treatment of premalignant stages. Targeting such CRAds with the RGD tripeptide could improve the utility of this adenoviral vector by creating a CAR-independent infection capability for tumor cells. To our knowledge, this is one of the first reported studies that has investigated the possibilities for adenoviral With light microscopy of the same material, the cultures of primary tumor material seemed to contain two cell populations with different morphology (lower panels). About 50% of the cells had a fibroblast-like morphology (black arrow); the remaining cells were smaller and had a more epithelial cell-like shape (white arrow). Original magnification: x10 objective. gene therapy to treat a gastrointestinal malignancy in primary tumor cells. However, we acknowledge that although this culture system is more resembling the in vivo situation than the established monoclonal cell lines, it is still an artificial monolayer test system. Because the complex three-dimensional structure of a tumor might influence the transduction efficiency of an adenoviral vector, the development of a system using cultured biopsies to test viral infection is currently under investigation.
It should also be noted that using the RGD virus will only partly solve the current difficulties with cancer gene therapy. Also, with this retargeted adenoviral vector it seems impossible to transduce 100% of the tumor cells, which is necessary to create efficient cancer treatment, and although this vector did establish a more efficient gene transfer in carcinoma cells in comparison to normal squamous epithelial cells, it did not create a selective viral transduction. Therefore, further research has to be focused on more selective targeting motifs before gene therapy can be incorporated in daily clinical practice. 30 
CONCLUSION
This study demonstrates that adenoviral entry via the primary adenoviral receptor CAR is limited in esophageal carcinoma cells. Adenoviral entry was increased when an integrin retargeted adenoviral vector was used. The increase in viral expression was not only due to an increase in the percentage of infected cells, but also to an increased gene expression per cell. Therefore, genetical targeting of the adenoviral vectors with an RGD tripeptide seems a promising treatment strategy to optimize cancer gene therapy.
Discussion
DR. J.R. IZBICKI: I would like to thank the Association for the privilege to discuss this very fine paper. You all know that gene therapy, especially esophageal cancer, is a hot topic. One of the main obstacles is that in gene therapy with viral transduction you can only reach a certain percentage of tumor cells. And this is probably the main reason for the therapeutic failures which we have seen in the past and I think that Dr. Buskens and her group have to be congratulated to tackle this issue.
I have some questions. The first is according the life span of the cell lines: when you consider the life span of the primary cell lines, that are typically reduced in contrast with the survival of the established cell lines, because these established cell lines are often genetically altered. What were the results and evaluation of the infection rate and death rate of the primary cell lines? In our studies, we have had problems with recurrent early infections of the primary cell cultures.
The second question: what are the rates of targeting normal cells in your model and have you done some studies about the effect on these accidentally targeted normal cells?
The last question: it is not possible to infect 100% of these carcinoma cells with this retargeted adenovirus, which seems to be crucial for the effectiveness of cancer gene therapy? What can we initially do to improve this? DR. C.J. BUSKENS: Thank you for your questions. Yes we did encounter some difficulties setting up the primary cell cultures. Sometimes, the cultures had to be terminated due to fungal overgrowth. This happened frequently when we used resection material from patients with an obstructing tumor or a candida esophagitis. If this was not the case, it was possible to maintain the cells in culture for several days. It was also technically possible to trypsinize the cells after a few days and culture them for several passages. However, then new problems developed with fibroblast overgrowth, and since the aim of this study was to analyze gene transfer in primary cells resembling the in vivo situation, we used for these experiments cells that were only cultured in vitro for 48 hours.
Your last question is very interesting. Even in cell lines with a population of monoclonal cells, it was never possible to transduce 100% of the cells. These experiments demonstrated that in heterogeneous primary cells the infection percentages were even lower, so indeed this is a problem. For curative gene therapy, it is essential to infect all tumor cells; therefore, it will definitely be necessary to either use a replication deficient adenoviral virus with a bystander effect on surrounding cells or a replication competent vector. However, with the results of the present vectors, it is more realistic that the current gene therapy for carcinomas will be used as a (neo)adjuvant therapy or in a palliative setting. These experiments demonstrate that an RGD-retargeted vector increases the transduction efficiency dramatically; therefore, we feel that using this virus will bring us one step further in optimizing cancer gene therapy for clinical purposes.
DR. M. REED: Could you comment on the distribution of the RGD receptor in more normal tissues. You just looked at normal epithelia, but it is expressed in vascular endothelium as well; and if you were administering it systemically, that would be crucial in terms of targeting.
DR. C.J. BUSKENS: We did analyze the presence of the CAR receptor and integrins in esophageal carcinoma cells and normal squamous epithelium of the esophagus, but not in vascular endothelium or other normal epithelium. However, if you want to administer the adenoviral vectors systemically, the RGD-retargeted virus will not be selective enough. The purpose of the inserted tripeptide is predominantly to increase the transduction efficiency. For a selective transduction of tumor cells, another targeting motif has to be used. An example is to target the vector with specific ligands (like a bi-specific antibody to EpCAM) so that the virus will only interact with receptors that are exclusively present on the surface of the carcinoma cells. Another possibility to achieve tumor-specific gene expression is with the use of tumorspecific promoters. Hereby, the virus is under the control of regulatory regions from proteins only expressed in carcinoma cells and not in normal epithelium (like cyclooxygenase-2), so that the therapeutic gene will not be transcribed in normal cells. DR. P.A. CLAVIEN: Congratulations for your very nice study. I think what we would like is a little bit more therapeutic or clinical aspects of what you have presented here. Your strategy to use a genetically retargeted adenovirus with modified fiber knobs is a sophisticated approach to make viral entry more specific for tumor cells. My first question: is your adenovirus a replicating or nonreplicating vector and what are the genes of interest? There is an adenovirus vector that selectively replicates in p53 mutated cells. Could you comment on your plans to use your modified virus for gene therapy? The second question is directed to the route of application. I am not sure if you plan to give the virus directly into the tumor, or do you plan to give it systematically? Could you speculate a little bit here what would be your further test that we can see this application in patients and the effectiveness in killing tumor cells.
DR. C.J. BUSKENS: These are very interesting questions. I think, as I said before, that it is too early for systemic administration of adenoviral vectors due to the hepatotropism of the virus and immune responses of the human body to the adenovirus type 5. So far, the clinical application of cancer gene therapy is limited to local administration intratumorally. This treatment with local injection of vectors into the tumor is preeminently suitable for the esophagus since this organ is easily accessible via endoscopy. However, even with this strategy, it remains important to transduce only carcinoma cells since normal mucosal cells neighboring the tumor are also at risk with the procedure and to avoid complications resulting from leakage of viruses to other cells in the body. Therefore, our therapeutic genes of interest are predominantly the conditionally replicating viruses like the ONYX-015 virus, which only replicates in p53-mutated cells. Currently, we are also investigating a transcriptionally targeted adenoviral vector that will only be transcribed in cyclooxygenase-2-positive cells, since we demonstrated in a previous study that the cyclooxygenase-2 expression in esophageal carcinoma cells is very high, whereas it is not expressed in normal squamous epithelial cells of the esophagus.
The last thing we are currently investigating to improve cancer gene therapy for clinical use is the use of other serotypes of adenoviral vectors (like serotypes 16 and 41). Most adults have been exposed to the adenovirus type 2 and 5; therefore, the use of other adenoviruses might prevent the systemic immune response. This would bring us one step closer to the desirable systemic administration of the adenoviral vector for curative cancer treatment.
